Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
COVID-19
COVID-19 Partnering Event
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
English
日本語
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Summit Therapeutics
June 27, 2018
Summit finds that Duchenne magic is not universal
February 09, 2018
Sarepta contains UK study halt, for now
January 26, 2018
DMD-day for investors
January 12, 2018
Upcoming events – Data dates for Summit and Cytokinetics
September 06, 2017
Sarepta hopes to pull off the same trick twice
March 16, 2017
Marathon’s hot potato is now PTC’s problem
March 16, 2017
Marathon’s hot potato is now PTC’s problem
October 14, 2016
Snippet roundup: Biomarin boosted, Synairgen stung
October 06, 2016
Therapy focus – Duchenne assets soar in the wake of Exondys 51 approval
October 06, 2016
Vantage point – What Brexit means for life science funding and strategy
October 05, 2016
Vantage point – What Brexit means for drug regulation
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 16, 2020
Evaluate Vantage COVID-19 Report
February 20, 2020
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
Editor's Picks
April 22, 2020
Covid-19 antibody tests face a very specific problem
April 23, 2020
Covid-19’s clinical damage starts to emerge
April 23, 2020
The crucial data readouts coming soon for small biotechs
April 22, 2020
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
April 03, 2020
The long path to an effective coronavirus vaccine
